Introduction
hematologic malignancies, Comorbidity
DISEASE, COMPLICATION, HEMATOLOGIC MALIGNANCIES, MALNUTRITION, DISEASE CHARACTERISTIC, COMPLICATIONS
One of the most promising treatments for patients with hematologic malignancies is allogeneic hematopoietic stem cell transplantation (allo-HSCT) (It can be challenging to select patients who will benefit from HSCT because survival after transplantation can vary greatly and rely on many factors. Various factors, including age at HSCT, complications, the donor type, the disease status as well as the conditioning regimen, can affect outcomes (To provide a score for pre-transplant risk and to better predict outcomes after allo-HSCT, several prognostic models have been performed. The Hematopoietic Cell Transplantation–specific Comorbidity Index (HCT-CI) and its derivation, the Comorbidity–Age Index, are derived from the complication condition of the patient (A thorough pre-transplant evaluation is essential at the time of assessing the risks and advantages of haplo-HCT. Therefore, It would be of tremendous clinical benefit for patients undergoing haplo-HSCT to develop a well-rounded pre-HSCT prognostic system that considers the risk elements associated with the patient and the disease. According to our knowledge, the prognostic implications of CAR in patients who received haplo-HSCT is unknown. Therefore, we hypothesized that integration of the inflammatory state, malnutrition, disease characteristics and comorbidities could provide a more comprehensive and precise prediction of overall survival (OS) than DRCI.